Jongeneel G, Greuter MJE, van Erning FN, et al. - Quality of life of patients should be incorporated into clinical decision making concerning the use of adjuvant chemotherapy (ACT) in stage II/III colon cancer, so researchers assessed quality of life, summarized as health utility (HU), in patients managed with and without ACT. They also examined the role of chemotherapy–induced peripheral neuropathy on HU. The participants were patients diagnosed with stage II/III colon cancer and engaging in the Prospective Dutch ColoRectal Cancer cohort. At baseline, 3, 6, 12, 18, and 24 months, HU scores were evaluated using the EQ‐5D‐5L. A significant difference of −0.039 in HU was revealed, by a mixed model, between patients managed with and without ACT. At 3 to 18 months post-diagnosis, patients treated with ACT demonstrated a significantly lower HU vs those managed without ACT. This difference was on the border of clinical importance and seemed to be partially associated with the sensory as well as motor neuropathy‐related side effects of ACT.